Ra Pharmaceuticals (RARX) Reports Positive Results from Phase 1b Pharmacokinetic Study of Zilucoplan (RA101495 SC) in Patients with Renal Impairment
Tweet Send to a Friend
Ra Pharmaceuticals, Inc. (NASDAQ: RARX) today announced positive results from the Company’s Phase 1b pharmacokinetic (PK) study evaluating zilucoplan (RA101495 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
